In Celexir’s body-recomposition toolkit, tesamorelin is positioned for patients who need targeted reduction of visceral adipose tissue (VAT) while preserving lean mass—useful in metabolic syndrome patterns and HIV-associated lipodystrophy. In practice, providers fold it into structured fat-loss programs alongside nutrition periodization, resistance training, sleep, and glucose control, leveraging Celexir’s ready-to-use formats and documentation to keep protocols consistent.
How it works: Tesamorelin is a GHRH analog that restores physiologic, pulsatile GH signaling—raising IGF-1 within the normal range, improving lipid mobilization, and supporting protein synthesis. This mechanism selectively trims VAT with relatively modest effects on subcutaneous fat, aligning with the “shrink the dangerous fat, keep the muscle” objective in longevity-minded body recomposition.
Evidence snapshot: Randomized trials in HIV-associated central adiposity show ~15–18% VAT reduction over ~26 weeks, with signals for improved body-image distress; MRI studies also report liver-fat reductions and small gains in trunk muscle density. Labels and reviews note class-consistent cautions—IGF-1 elevation, fluid retention, and glucose intolerance/diabetes risk in susceptible patients—so monitor IGF-1 and glycemia and individualize continuation to responders.
Use & dosing (context): Celexir catalog guidance lists ~1 mg daily with GMP documentation and cold-chain handling; approved U.S. products differ by formulation—EGRIFTA SV® 1.4 mg SC once daily and EGRIFTA WR® 1.28 mg SC once daily—and are not interchangeable. Align protocol, patient selection, and monitoring with these formulation specifics, and track objective markers (waist/VAT by imaging when feasible, A1c, lipids, CRP, lean mass, functional capacity).